Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the ...

Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic collaborations, while navigating financial hurdles and development risks.

MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into ...

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic ...

Detailed price information for Mink Therapeutics Inc (INKT-Q) from The Globe and Mail including charting and trades.

Thank you, Stefanie. For those new to MiNK Therapeutics, we are advancing a clinically validated allogeneic invariant natural killer T cell platform, one that is fundamentally differentiated in its ...

It is interesting to see that Mink, the Icelandic funky camper brand, doesn’t once mention the word "caravan" in the press release for its upcoming Mink-E model. Perhaps that’s because it considers ...